WO2013184037A2 - Антибактериальная фармацевтическая композиция - Google Patents
Антибактериальная фармацевтическая композиция Download PDFInfo
- Publication number
- WO2013184037A2 WO2013184037A2 PCT/RU2013/000467 RU2013000467W WO2013184037A2 WO 2013184037 A2 WO2013184037 A2 WO 2013184037A2 RU 2013000467 W RU2013000467 W RU 2013000467W WO 2013184037 A2 WO2013184037 A2 WO 2013184037A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azithromycin
- solvents
- antioxidant
- pyrrolidone
- preservative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the invention relates to the field of veterinary medicine and can be used for the prevention and treatment of bacterial infections.
- Azithromycia is active against gram-positive microorganisms: Streptococcus spp. (groups C, F and G, except for those resistant to erythromycin), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus viridans, Staphylococcus epidermidis, Staphylococcus aureus; gram-negative bacteria: Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Legionella pneumophila, Haemophilus ducreyi, Campylobacter jejuni, Neisseria gonorrhoeae and Gardnerella vaginalis; some anaerobic microorganisms: Bacteroides bivius, Clostridium perfringens, Peptostreptococcus spp; as well as Chlamydi
- azithromycin with malonic acid were isolated. These compounds can be used to prepare instant forms of azithromycin for oral administration (US Pat. Co., Tae Hun Song, Han Kyong Kim, Kwee Hyun Suh, Gwansum Lee, crystalline azithromycin L-malate monohydrate and pharmaceutical composition containing same).
- a solid dosage form containing lyophilized azithromycin is known (US patent G ° 01 16336 dated 1.07.2006 Byung No Woo, K. Keith Knwok, Kang Yong Yang, lyophilized azithromycin formulation). There is a lyophilized form of azithromycin with the commercial name "Sumamed” produced by Pliva.
- This dosage form is a sterile powder for the preparation of an injection solution immediately before use, since the antibiotic in this solution quickly decomposes.
- this dosage form contains ethyl alcohol, therefore it cannot be administered intramuscularly or subcutaneously, as this will lead to the development of tissue necrosis. It is used only intravenously and in dilute aqueous solution. Thus, this is not a ready-to-use injection solution, but a concentrate that is added to an intravenous infusion solution.
- the objective of the present invention is to design a preparation based on azithromycin in the form of a solution having a wide spectrum of antimicrobial action, in the form of an injection solution ready for use not only for intravenous, but also for intramuscular, subcutaneous, intrauterine and intracisternal administration.
- the technical result is a high physico-chemical stability (at least 18 months) of a liquid dosage form, while ensuring safety for the treatment and prevention of diseases caused by pathogenic microorganisms.
- the preservative according to the invention further comprises an antioxidant, ascorbic acid or sodium ascorbate or calcium ascorbate or palmityl ascorbate or 4-methyl-2 are used as antioxidant.
- an antioxidant ascorbic acid or sodium ascorbate or calcium ascorbate or palmityl ascorbate or 4-methyl-2 are used as antioxidant.
- Organic solvents such as dimethylacetamide or dimethyl sulfoxide or N-methyl-2-pyrrolidone or Y-ethyl-2-pyrrolidone or M-ethoxy-2-pyrrolidone or N-octyl-2-pyrrolidone or 3.3 can be used as solvents or cosolvents dimethyl-2-pyrrolidone, propylene glycol or transcutol (diethylene glycol monoethyl ether) or benzyl alcohol, or combinations thereof; or water or a combination of organic solvents with water.
- the composition may further comprise a pH adjuster in an amount of up to 5%; solubilizer polyethylene glycol 660 12-hydroxy stearate or poloxamer F 68 or poloxamer F 127 or polyoxyethylene glycerol triricinoleate or polyoxyethylene glycerol trihydroxystearate or polyoxyethylene sorbitan monooleate or combinations thereof in an amount of 1-30%; anesthetic up to 2.0%.
- a pH adjuster in an amount of up to 5%
- anesthetic up to 2.0%.
- the active substance is dissolved in a mixture of an organic solvent and water with the addition of substances that stabilize the acidity of the solution.
- the ratios of the organic solvent, water and pH (acidity) regulators are selected so that the physicochemical stability of the solution is as possible as possible with a minimum degree of degradation dissolved azithromycia.
- the organic solvent and pH regulator were selected according to the criterion of least toxicity with intramuscular and subcutaneous administration.
- the invention is illustrated in the graph, which shows the data on the degradation of azithromycia solutions made according to the examples of the following formulations 1-9.
- the developed drug is a stable solution of the active ingredient - azithromycia.
- a solvent and / or co-solvent water, dimethyl sulfoxide or 2-pyrrolidone or N-methyl-2-pyrrolidone or M-ethyl-2-pyrrolidone and / or K-ethoxy-2-pyrrolidone or N-octyl-2-pyrrolidone or dimethylacetamide or 3,3-dimethyl-2-pyrrolidone or propylene glycol or traiskutol (diethylene glycol monoethyl ether) or combinations thereof.
- pH regulators citric acid or malic acid or benzoic acid or succinic acid or combinations thereof are used.
- antioxidants ascorbic acid or sodium ascorbate or calcium ascorbate or palmityl ascorbate or 4-methyl-2, b-ditretbutylphenol or tertbutylhydroquinone, 2,4,5-trihydroxybutyrophione or sodium metabisulfite or tocopherol acetate or thioglycerol or combinations thereof are used.
- a dosage form may include a solubilizer.
- a solubilizer use Cremophor EL or Cremophor ELP (polyoxyethylene glycerol triricinoleate), or Cremophor RH40 (polyoxyethylene glycerol trihydroxystearate), or Tween 80 (polyoxyethylene sorbitan monooleate), or Solutol HS 15-6-polyethylene-12-polyethylene ) or poloxamer F68 or poloxamer F127 (Polyoxyethylene-polyoxypropylene block copolymer), or combinations thereof.
- the dosage form may include aEgestetic. Lidocaine hydrochloride up to 0.5% is used as an anesthetic.
- azithromycia content in the solution was measured by HPLC based on the method provided by the State Pharmacopoeia of the Russian Federation XII, FS Azithromycin.
- the most optimal solvents are M-methyl-2-pyrrolidone and dimethylacetamide.
- the solubility of azithromycin increases to 50% (see example N "9).
- Azithromycin is suspended in an appropriate solvent or mixture of solvents, then a pH regulator, solubilizer, anesthetic, preservative, antioxidant are added.
- Example JV ° 1 Example JV ° 1
- composition containing the anesthetic is given.
- a formulation with a solubilizer (polyoxyethylene-glycerol-tricinoleate) and the corresponding amount of other components is given. Name of components Amount, wt.%
- composition of the dosage form of the regulator negatively affects the stability of the solution (rapid darkening, drop in the concentration of the active substance), in addition, an increase in the amount of organic solvent above 70% leads to an increase in the toxic properties of the dosage form.
- a decrease in the amount of solubilizer below 5.0% leads to a decrease in the stability of the dosage form (precipitation), in addition, a decrease in the amount of active substance leads to a decrease in the therapeutic effectiveness of the dosage form.
- the formulation is presented using poloxamer F 1 27 as a solubilizer without adding an organic co-solvent and characterized by the high content of azithromycia in example JNS 6: Name of components Amount, wt.%
- a formulation is given where propylene glycol is used as an organic solvent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2016MUN2014 IN2014MN02016A (ru) | 2012-06-08 | 2013-06-06 | |
EP13800655.6A EP2859885A4 (de) | 2012-06-08 | 2013-06-06 | Antibakterielle pharmazeutische zusammensetzung |
US14/395,483 US20150126466A1 (en) | 2012-06-08 | 2013-06-06 | Antibacterial pharmaceutical composition |
MX2014011345A MX361596B (es) | 2012-06-08 | 2013-06-06 | Composición farmacéutica inyectable antibacterial. |
CN201380019631.1A CN104470502B (zh) | 2012-06-08 | 2013-06-06 | 抗细菌药物组合物 |
BR112014025017A BR112014025017A2 (pt) | 2012-06-08 | 2013-06-06 | Composição farmacêutica injetável antibacteriana |
EA201400830A EA027144B1 (ru) | 2012-06-08 | 2013-06-06 | Антибактериальная инъекционная фармацевтическая композиция |
US15/792,970 US20180042953A1 (en) | 2012-06-08 | 2017-10-25 | Antibacterial injectable pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012123616/15A RU2512683C2 (ru) | 2012-06-08 | 2012-06-08 | Антибактериальная инъекционная фармацевтическая композиция |
RU2012123616 | 2012-06-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/395,483 A-371-Of-International US20150126466A1 (en) | 2012-06-08 | 2013-06-06 | Antibacterial pharmaceutical composition |
US201715630151A Continuation | 2012-06-08 | 2017-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013184037A2 true WO2013184037A2 (ru) | 2013-12-12 |
WO2013184037A3 WO2013184037A3 (ru) | 2014-04-03 |
Family
ID=49712781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2013/000467 WO2013184037A2 (ru) | 2012-06-08 | 2013-06-06 | Антибактериальная фармацевтическая композиция |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150126466A1 (ru) |
EP (1) | EP2859885A4 (ru) |
CN (1) | CN104470502B (ru) |
BR (1) | BR112014025017A2 (ru) |
EA (1) | EA027144B1 (ru) |
IN (1) | IN2014MN02016A (ru) |
MX (1) | MX361596B (ru) |
RU (1) | RU2512683C2 (ru) |
WO (1) | WO2013184037A2 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2563826C1 (ru) * | 2014-08-21 | 2015-09-20 | Общество с ограниченной ответственностью "Научно-внедренческий центр Агроветзащита" | Инъекционная антибактериальная фармацевтическая композиция |
CN108721209A (zh) * | 2017-04-20 | 2018-11-02 | 广东东阳光药业有限公司 | 一种兽用阿奇霉素注射剂 |
RU2666607C1 (ru) * | 2017-05-03 | 2018-09-11 | Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" | Способ повышения стабильности инъекционной фармацевтической композиции |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277829B1 (en) | 1999-08-09 | 2001-08-21 | S.I.F.I. Societa Industria Farmaceutica Italiana S.P.A. | Process for preparing of aqueous formulation for opthalmic use |
CN1613453A (zh) | 2003-11-04 | 2005-05-11 | 山西亚宝药业集团股份有限公司 | 一种阿奇霉素注射液及制备方法 |
US20050106239A1 (en) | 2001-10-18 | 2005-05-19 | Ruth Tenengauzer | Stabilized azithromycin compositions |
US20060116336A1 (en) | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
US7064104B2 (en) | 2003-06-13 | 2006-06-20 | The Procter & Gamble Company | Methods of managing the symptoms of premenstrual syndrome |
US20070185194A1 (en) | 2003-07-01 | 2007-08-09 | Kamal Mehta | Stable oral compositions of azithromycin monohydrate |
US20080096831A1 (en) | 2003-11-06 | 2008-04-24 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
US7572773B2 (en) | 2003-07-24 | 2009-08-11 | Pliva Hrvatska D.O.O. | Single dose fast dissolving azithromycin |
US20090318375A1 (en) | 2005-06-08 | 2009-12-24 | Hanmi Pharm Co., Ltd | Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1205338A (zh) * | 1998-05-08 | 1999-01-20 | 刘万忠 | 阿奇霉素水溶性盐的合成新方法及其在医药上的用途 |
US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
US6787342B2 (en) * | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
US20080149521A9 (en) * | 2001-10-18 | 2008-06-26 | Michael Pesachovich | Methods of stabilizing azithromycin |
RU2255730C1 (ru) * | 2003-10-14 | 2005-07-10 | Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") | Стабильная фармацевтическая суспензия азитромицина и способ ее получения |
RU2327453C2 (ru) * | 2006-03-28 | 2008-06-27 | Управление ветеринарии Курской области | Состав для терапии и профилактики инфекционных заболеваний животных |
US7795231B2 (en) * | 2007-10-04 | 2010-09-14 | Insite Vision Incorporated | Concentrated aqueous azalide formulations |
CN101244076B (zh) * | 2008-03-24 | 2012-10-31 | 南京华威医药科技开发有限公司 | 一种阿奇霉素眼用药物组合物 |
CN101683532A (zh) * | 2008-09-25 | 2010-03-31 | 武汉诺安药业有限公司 | 含玻璃酸或其盐的眼用复方药物制剂 |
CN101874808A (zh) * | 2010-05-12 | 2010-11-03 | 邓学峰 | 阿奇霉素组合药物 |
CN102283799B (zh) * | 2011-08-17 | 2013-07-31 | 北京乐维生物技术有限公司 | 一种阿奇霉素凝胶型滴眼液及其制备工艺 |
-
2012
- 2012-06-08 RU RU2012123616/15A patent/RU2512683C2/ru active
-
2013
- 2013-06-06 EP EP13800655.6A patent/EP2859885A4/de not_active Withdrawn
- 2013-06-06 CN CN201380019631.1A patent/CN104470502B/zh not_active Expired - Fee Related
- 2013-06-06 IN IN2016MUN2014 patent/IN2014MN02016A/en unknown
- 2013-06-06 US US14/395,483 patent/US20150126466A1/en not_active Abandoned
- 2013-06-06 BR BR112014025017A patent/BR112014025017A2/pt not_active Application Discontinuation
- 2013-06-06 EA EA201400830A patent/EA027144B1/ru not_active IP Right Cessation
- 2013-06-06 WO PCT/RU2013/000467 patent/WO2013184037A2/ru active Application Filing
- 2013-06-06 MX MX2014011345A patent/MX361596B/es active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277829B1 (en) | 1999-08-09 | 2001-08-21 | S.I.F.I. Societa Industria Farmaceutica Italiana S.P.A. | Process for preparing of aqueous formulation for opthalmic use |
US20050106239A1 (en) | 2001-10-18 | 2005-05-19 | Ruth Tenengauzer | Stabilized azithromycin compositions |
US7064104B2 (en) | 2003-06-13 | 2006-06-20 | The Procter & Gamble Company | Methods of managing the symptoms of premenstrual syndrome |
US20070185194A1 (en) | 2003-07-01 | 2007-08-09 | Kamal Mehta | Stable oral compositions of azithromycin monohydrate |
US7572773B2 (en) | 2003-07-24 | 2009-08-11 | Pliva Hrvatska D.O.O. | Single dose fast dissolving azithromycin |
CN1613453A (zh) | 2003-11-04 | 2005-05-11 | 山西亚宝药业集团股份有限公司 | 一种阿奇霉素注射液及制备方法 |
US20080096831A1 (en) | 2003-11-06 | 2008-04-24 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
US20060116336A1 (en) | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
US20090318375A1 (en) | 2005-06-08 | 2009-12-24 | Hanmi Pharm Co., Ltd | Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same |
Non-Patent Citations (1)
Title |
---|
See also references of EP2859885A4 |
Also Published As
Publication number | Publication date |
---|---|
EA201400830A1 (ru) | 2014-11-28 |
RU2512683C2 (ru) | 2014-04-10 |
BR112014025017A2 (pt) | 2017-08-22 |
MX2014011345A (es) | 2015-05-11 |
EA027144B1 (ru) | 2017-06-30 |
MX361596B (es) | 2018-12-11 |
CN104470502A (zh) | 2015-03-25 |
IN2014MN02016A (ru) | 2015-08-07 |
EP2859885A4 (de) | 2016-05-25 |
WO2013184037A3 (ru) | 2014-04-03 |
US20150126466A1 (en) | 2015-05-07 |
EP2859885A2 (de) | 2015-04-15 |
RU2012123616A (ru) | 2013-12-20 |
CN104470502B (zh) | 2018-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3893059B2 (ja) | アザライド系抗生物質組成物 | |
US5773422A (en) | Avermectin formulation | |
KR20150027265A (ko) | 소수성 조성물용 생분해성 약물 전달 | |
CN108055825A (zh) | 包含异噁唑啉活性剂的延长释放可注射制剂、其方法和用途 | |
WO2013184037A2 (ru) | Антибактериальная фармацевтическая композиция | |
WO2011035108A1 (en) | Formulations of daptomycin | |
RU2019142111A (ru) | Усилитель противоопухолевого эффекта с применением нового соединения бифенила | |
WO2006054315B1 (en) | Nonaqueous liquid parenteral aceclofenac formulation | |
WO2011014541A1 (en) | Stable formulations of azacitidine | |
CN108601730B (zh) | 万古霉素的制剂 | |
WO2023192602A2 (en) | Respiratory stimulant nasal formulations | |
CN101077352A (zh) | 含乳糖酸阿奇霉素的眼用制剂 | |
KR20170080666A (ko) | 안과용 수성 조성물 | |
KR102138392B1 (ko) | 신경근 차단제의 안정화된 수성 조성물 | |
WO2010096551A2 (en) | Antimicrobial compositions | |
EP2958554A1 (en) | Stable compositions of bendamustine | |
WO2020081839A1 (en) | Methods and compositions for treating oral mucositis | |
KR20220035954A (ko) | 항진균약을 유효성분으로 하는 의약 조성물 | |
US20180042953A1 (en) | Antibacterial injectable pharmaceutical composition | |
JP2010105965A (ja) | バンコマイシン製剤 | |
RU2666607C1 (ru) | Способ повышения стабильности инъекционной фармацевтической композиции | |
WO2022025831A1 (en) | Pharmaceutical compositions for injection comprising tulathromycin | |
CN115867267A (zh) | RORγt抑制剂和其局部用途 | |
JP2022500350A (ja) | 安定したアザシチジン含有医薬組成物の製造方法 | |
KR101774218B1 (ko) | 동물용 복합항생제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201400830 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/011345 Country of ref document: MX |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13800655 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14395483 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014025017 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014025017 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141007 |